Authored By: Sarah
11 Jul 2024

 Idiopathic Pulmonary Fibrosis Market Size to grow by USD 1360.99 million between 2023-2027

According to a research report “ Idiopathic Pulmonary Fibrosis Market” by Route Of Administration (Oral, Parenteral) Drug Class (Systemic corticosteroids, Immunosuppressants, Tyrosine kinase inhibitors, Anti-fibrotic agents) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2027 published by Technavio, the market size is estimated to grow by USD 1360.99 million, at a CAGR of  6.68% during the forecast period. Idiopathic Pulmonary Fibrosis (IPF) is a progressive and fatal lung disease, characterized by the scarring of lung tissue, impairing the ability for effective oxygen transfer to the bloodstream. This condition, affecting thousands globally, results in breathing difficulties and decreased quality of life. Prevalence rates have risen significantly, with increased diagnoses across all demographics, particularly among the elderly population. Factors contributing to this trend include an aging demographic and unhealthy dietary habits, which exacerbate respiratory diseases. Healthcare providers and researchers are increasingly concerned with this trend, as IPF poses significant challenges to patient care and treatment.

Browse market data tables, figures, and in-depth TOC on “Idiopathic Pulmonary Fibrosis Market” by Route Of Administration (Oral, Parenteral) Drug Class (Systemic corticosteroids, Immunosuppressants, Tyrosine kinase inhibitors, Anti-fibrotic agents) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2027. Download Free Sample

 

By Route Of Administration, the Oral segment is projected to dominate the market size in 2024

In the business context of the Idiopathic Pulmonary Fibrosis (IPF) market, systemic corticosteroids have long been utilized for the treatment of various respiratory ailments, including IPF. These medications primarily function to decrease inflammation and stimulate lung tissue healing. However, the optimal steroid dosage and duration for IPF patients remain uncertain, necessitating further research to establish their safety and efficacy. Given these concerns, the pharmaceutical industry has developed alternative therapies, such as pirfenidone and nintedanib, which have demonstrated the ability to slow disease progression and enhance lung function in IPF patients, without the detrimental side effects linked to corticosteroids. Nevertheless, corticosteroids continue to be commonly employed, particularly among IPF patients experiencing acute exacerbations.

By Drug Class, Systemic corticosteroids  segment is expected to hold the largest market size for the year 2024

In the business context of Idiopathic Pulmonary Fibrosis (IPF) treatment, the oral route of medication administration offers numerous advantages for patients. This non-invasive method, which includes tablets, capsules, and liquid solutions, is preferred due to its ease, convenience, and home-based application. Notably, the US FDA has approved two oral medications, nintedanib and pirfenidone, for IPF treatment. Nintedanib, a tyrosine kinase inhibitor, targets multiple growth factors implicated in lung fibrosis progression.

North America is forecasted to hold the largest market size by region in 2024

The idiopathic pulmonary fibrosis (IPF) market in North America is poised for substantial expansion due to the escalating incidence of respiratory disorders, including IPF. The aging population is a significant contributing factor to the rising demand for IPF treatments and pharmaceuticals in this region. According to the American Lung Association, IPF predominantly affects individuals above the age of 60, making the elderly demographic a significant market opportunity. With the ongoing demographic shift in North America, the prevalence of IPF is projected to increase, offering substantial growth prospects for industry participants within the forecast period.

The Idiopathic Pulmonary Fibrosis Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Alembic Pharmaceuticals Ltd.
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Celix Pharma Ltd.
  • Cipla Ltd.
  • Daewoong Pharmaceutical Co. Ltd.
  • F. Hoffmann La Roche Ltd.
  • FibroGen Inc.
  • Galapagos NV
  • Galecto Inc.
  • GNI Group Ltd.
  • Horizon Therapeutics Plc
  • Intas Pharmaceuticals Ltd.
  • Jubilant Pharmova Ltd.
  • Liminal BioSciences Inc.
  • MediciNova Inc.
  • Merck and Co. Inc.
  • Mission Therapeutics
  • Novartis AG
  • Shionogi and Co. Ltd.
  • United Therapeutics Corp.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease of unknown cause. The treatment for IPF involves multidisciplinary care teams that include pulmonologists, radiologists, pathologists, and other specialists. Diagnostic services such as high-resolution computed tomography (HRCT) scans and biopsies are essential for accurate diagnosis. The primary treatment options for IPF include antifibrotic agents like Nintedanib and Pirfenidone, which have been shown to improve quality of life and patient outcomes. Targeted therapies and immunosuppressants may also be used in certain cases. Pharmacies, both online and retail, play a crucial role in the delivery of these medications. Hospital pharmacies may be involved in the administration of these drugs during hospitalization. Hospitals and clinics provide medical care and therapeutic approaches to manage respiratory difficulties and impaired lung function associated with IPF. Diagnostic technologies continue to evolve, with research exploring the potential of biomarkers and artificial intelligence in aiding diagnosis and monitoring disease progression. The application of these advancements in IPF care is an area of ongoing research and development.

Market Research Overview

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by breathing difficulties and impaired lung function. The diagnosis and treatment of IPF require specialized medical care, which can be accessed through hospitals and outpatient facilities. Diagnostic procedures, such as high-resolution CT scans and pulmonary function tests, are essential for accurate diagnosis. A promising trend in IPF care is the application of telemedicine solutions, which enable remote monitoring and consultation for patients, particularly those in rural areas or with mobility issues. Personalized treatment options, including targeted therapies like Nintedanib and Pirfenidone, immunosuppressants, and antifibrotic agents, are becoming increasingly important in managing IPF. However, financial barriers, such as healthcare spending and reimbursement policies, can limit access to these treatments, particularly for the geriatric population, who are disproportionately affected by IPF. Multidisciplinary care teams, including respiratory specialists, pharmacists, and other healthcare providers, are essential for effective IPF management. Diagnostic technologies, such as online providers, retail pharmacies, hospital pharmacies, and clinical trials, play a crucial role in IPF care. Medical research and drug development continue to offer new therapeutic approaches to improve patient outcomes and quality of life. Ultimately, a collaborative effort between healthcare providers, patients, and policymakers is necessary to address the challenges of IPF and improve access to effective treatment options.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio